Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

38.5%

10 terminated/withdrawn out of 26 trials

Success Rate

54.5%

-32.0% vs industry average

Late-Stage Pipeline

15%

4 trials in Phase 3/4

Results Transparency

100%

12 of 12 completed trials have results

Key Signals

12 with results10 terminated

Enrollment Performance

Analytics

Phase 2

12(52.2%)

N/A

5(21.7%)

Phase 3

2(8.7%)

Phase 1

2(8.7%)

Phase 4

2(8.7%)

23Total

Phase 2(12)

N/A(5)

Phase 3(2)

Phase 1(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (26)

Showing 20 of 26 trials

NCT01416831Phase 2Active Not Recruiting

Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.

Role: collaborator

NCT02964078Phase 2Completed

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Role: collaborator

NCT00338377Phase 2Active Not Recruiting

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Role: collaborator

NCT01366092Phase 2Active Not Recruiting

Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

Role: collaborator

NCT02340676Phase 2Completed

A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD

Role: collaborator

NCT03260504Phase 1Terminated

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Role: collaborator

NCT02306954Phase 2Active Not Recruiting

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

Role: collaborator

NCT03476174Phase 2Terminated

Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma

Role: collaborator

NCT01896271Phase 2Completed

High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer

Role: collaborator

NCT02624037Not ApplicableCompleted

Precision IFX: Using a Dashboard to Individualize Infliximab Dosage

Role: collaborator

NCT01683188Phase 4Terminated

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Role: collaborator

NCT01854242Completed

Study of the Relationship Between Glycogen Storage Disease Type Ia and Inflammatory Bowel Disease

Role: collaborator

NCT01550367Phase 1Completed

Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

Role: collaborator

NCT03064815Not ApplicableCompleted

The SpACE Study - Small Bowel Crohn's Disease and Spondyloarthropathies

Role: collaborator

NCT02793778Phase 2Terminated

Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Therapy

Role: lead

NCT01415167Completed

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Role: lead

NCT03566407Not ApplicableTerminated

Blood and Stool Molecular Biomarkers Longitudinal Detection Study in Crohn's Disease (CD) Patients

Role: lead

NCT02796352Phase 2Terminated

A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study

Role: collaborator

NCT00113503Phase 2Terminated

Imuran Dosing in Crohn's Disease Study

Role: collaborator

NCT02849951Phase 3Terminated

A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)

Role: lead